drugset / Trial / NCT04191421
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Phase 1/2
Completed
35 enrolled
Emory University
EUSA Pharma, Inc. · collabNational Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collabNovartis · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase Ib/II trial studies the best dose and side effects of siltuximab and how well it works in combination with spartalizumab in treating patients with pancreatic cancer that has spread to other places in the body. Monoclonal antibodies, such as siltuximab and spartalizumab, interfere with the ability of tumors cells to grow and spread.
Timeline
- Start
- 2020-01-17
- Primary completion
- 2023-04-05
- Completion
- 2023-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siltuximab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 9 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 11 mg/kg | Intravenous |
| Subject | Spartalizumab | Monoclonal antibody | 300 mg | Intravenous |